Over the past four decades, MIT has had a focused effort in cancer research, first in the form of the MIT Center for Cancer Research (CCR) and, since 2007, as the Koch Institute for Integrative Cancer Research at MIT. This effort has been continuously supported by a Cancer Center Support Grant (CCSG) from the National Cancer Institute (NCI), providing the designation as an NCI-designated Cancer Center at MIT. By supplying infrastructural support for Core Facilities and other organizational components of the Koch Institute as well as funds for faculty recruitment and pilot projects, this CCSG is a critical resource for cancer research at MIT. From the establishment of the CCR in 1974 to the transition to the Koch Institute and continuing to the present, the NCI Cancer Center designation has had a strong influence on the MIT administration, leading to significant institutional support over this entire period. The investment in construction of the Koch Institute building (opened in late 2010) is a recent indication of this support. The building brings together 27 cancer scientists and cancer-oriented engineers to form a highly inter-disciplinary and collaborative research environment. The building is also the hub of cancer research on the MIT campus, with a nearly equal number of Members of the Center having their laboratories in other research buildings nearby. The 56 Center Members are drawn from eight academic departments at the School of Science or School of Engineering at MIT. Beyond the discovery research and technology development being pursued by the Members of this Center, significant emphasis is placed on translational research in the form of collaborations with clinical centers and industry partners. Research in the Koch Institute is organized into three Programs. Each of these Programs has made significant advances over the current grant period. Program 1: Genetic & Cellular Programs in Cancer is co-led by Drs. Phillip Sharp, J Christopher Love, and Eliezer Calo. Program 2: Cancer Biology & Immunology is co-led by Drs. Richard Hynes, Dane Wittrup, and Stefani Spranger. Program 3: Systems and Engineering Approaches to Cancer is co-led by Drs. Michael Yaffe, Scott Manalis, and Angela Koehler. These Programs function to stimulate new research initiatives by their Members as well as to foster intra- and inter-programmatic collaborations. In aggregate the 56 Members of this Center have published 1006 cancer-related articles over the past grant period. Of those, nearly 18% have involved multiple Members. The Center has a cancer-related funding base of $58,596,507 TDC (see Data Tables 2A/2B).

Public Health Relevance

The Koch Institute for Integrative Cancer Research at MIT is a highly inter-disciplinary Cancer Center that brings together the great strengths at MIT in cancer science and cancer-oriented engineering to address long- standing problems in the diagnosis and treatment of cancer. The Koch Institute is focused on basic discovery and technology development; however, advancing projects toward the clinic and to the benefit of patients as rapidly as possible is a high priority. This occurs through extensive interactions with clinical centers as well as industry partners.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014051-49
Application #
9937086
Study Section
Subcommittee H - Clinical Groups (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-06-17
Project End
2025-04-30
Budget Start
2020-06-01
Budget End
2021-04-30
Support Year
49
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Miscellaneous
Type
Organized Research Units
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Lannagan, Tamsin R M; Lee, Young K; Wang, Tongtong et al. (2018) Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut :
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Roper, Jatin; Tammela, Tuomas; Akkad, Adam et al. (2018) Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. Nat Protoc 13:217-234
Suzuki, Hiroshi I; Spengler, Ryan M; Grigelioniene, Giedre et al. (2018) Deconvolution of seed and RNA-binding protein crosstalk in RNAi-based functional genomics. Nat Genet 50:657-661
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Richardson, Christopher E R; Cunden, Lisa S; Butty, Vincent L et al. (2018) A Method for Selective Depletion of Zn(II) Ions from Complex Biological Media and Evaluation of Cellular Consequences of Zn(II) Deficiency. J Am Chem Soc 140:2413-2416
Choudhury, Atish D; Werner, Lillian; Francini, Edoardo et al. (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:
Chen, Pan-Yu; Muzumdar, Mandar Deepak; Dorans, Kimberly Judith et al. (2018) Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 78:985-1002
Wong, Madeline Y; Chen, Kenny; Antonopoulos, Aristotelis et al. (2018) XBP1s activation can globally remodel N-glycan structure distribution patterns. Proc Natl Acad Sci U S A 115:E10089-E10098
Viswanathan, Srinivas R; Nogueira, Marina F; Buss, Colin G et al. (2018) Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50:937-943

Showing the most recent 10 out of 904 publications